Ga mafi yawan mutane a yau, chemotherapy yana nufin irin cytotoxic, ko kashewar cell, magani wanda ake amfani dasu don magance ciwon daji. Amma, asali, chemotherapy wani lokaci ne wanda likitan kasar Jamus Paul Ehrlich ya tsara, wanda ya yi amfani da ita don nufin kawai amfani da sinadarai don magance cutar. Sabili da haka, "ƙwaƙwalwar ƙwayoyi" na iya haɗawa da duk wani abu daga maganin rigakafi ko ma da mahimmanci, magungunan ƙwayoyin magunguna , tun da sun ƙunshi sunadarai kuma ana amfani da su don magance cutar.
A yau, wasu suna la'akari da " maganin ciwon daji na ciwon daji " a tsakanin waɗanda ke da ƙananan sakamako. Duk da haka, sau da yawa shine yanayin da ake amfani da waɗannan hanyoyin shan magani ta hanyar tare da kwararrun ƙwayar cuta, ba kawai. Kuma, kodayake kwayoyin maganin magungunan ba su shafi jiki ba daidai da yadda ma'aikatan chemotherapy ke yi, har yanzu suna iya haifar da tasiri. Kwayoyin ciwon daji zasu iya samun ƙarin mai karɓa ko manufa fiye da kwayoyin lafiya - wanda aka yi niyya don maganin ƙwaƙwalwa zai iya amfani da ita - amma sassan lafiya yana iya zamawa.
Ƙwararren Magana
Matsarar maganin ciwon magungunan zai zama wani abu kamar harsashi mai sihiri, kuma saboda yawancin rashin lafiya, farfadowa mafi kyau ba a wanzu ba. A ƙarshen 1800s da farkon farkon 1900, masana kimiyya sun fara koyi game da kwayoyin cuta da kuma cututtuka masu cutar na cutar. Paul Ehrlich likita ne wanda yayi aiki tare da kwayoyin cuta, kuma ya yi imani cewa, tun da yake zai iya cire kwayoyin cutar kuma ya gan su a ƙarƙashin microscope, ya kamata ya iya kaiwa wadannan hare-haren idan ya iya samun sinadaran da zai hada kansa da kwayar cutar. kashe shi, barin duk abin da ba shi da lafiya.
Ya kira irin wadannan magungunan sihiri.
A yau, muna da sifofin wadannan harsunan sihiri da aka sani da maganin rigakafi, amma har ma magungunan maganin rigakafi na iya kasancewa da tasiri - ko mafi muni, na iya haifar da haɗari a cikin wasu mutane da ake kira hypersensitivity. Wannan ba yana nufin barin sama da ra'ayin mahimmin sihiri ba, duk da haka.
Amfani da Maɗaukaki
Abin takaici, yawancin cututtuka na ciwon daji na yau da kullum suna hade da muhimmancin guba. Kwayoyin ciwon daji sukan taso ne daga al'ada, kwayoyin lafiya waɗanda suka tara lahani - sakamakon hakan ya haifar da girma. Sun bambanta ne daga kwayoyin halitta wadanda likitoci zasu iya amfani da maganin maganin cututtukan kwayar cutar daji a cikin mafi girma fiye da kwayoyin lafiya, amma wasu kwayoyin lafiya sun shawo kan su; Wadannan marasa lafiya suna cike da cutar ta hanyar likita, don amfani da kwayar cutar kanjamau da kuma kokarin yada rayuwar mutum.
Wani lokaci akwai dangantaka ta kai tsaye tsakanin ci gaba da maganin ciwon daji da kuma kara yawan ƙwayar cuta. A gefe guda kuma, masana kimiyya da ke nazarin sakamakon gwajin gwaji sun kasance a kan kullun neman maki inda karuwar kwayar magani ba ta samo dukiya amma yana hade da mafi yawan maye. Yawancin lokaci, aikin daidaitawa ne da likitoci da marasa lafiya suke yi tare - yana nufin mafi girma da inganci tare da matakin mai guba wanda ya yarda, domin ya sami nasarori na dogon lokaci.
Marayun tsofaffi
Kodayake yana iya zama mai ban mamaki ga mutane da yawa, wasu gwajin ciwon daji suna amfani da shekarun shekaru 60-65 a matsayin ƙofar ga marasa lafiya "tsofaffi".
A bayyane yake, kalmar tsofaffi na iya zama kalma mai mahimmanci kamar yadda wasu mutane a cikin shekarunsu 80 da 90 sun fi lafiya fiye da mutane da dama da shekarunsu suka yi. Yayin da muke da shekaru, duk da haka, muna nuna ingantaccen yanayin kiwon lafiya, kamar cutar hawan jini. Kuma kodanmu ba sau da yawa a matsayin tsabta a tsaftace jini kamar yadda suke. Don wadannan dalilai da dalilai masu yawa, ƙwarewarmu na jure waƙar kariya, a matsakaici, ba shi da kyau a shekaru 85 da haihuwa kamar yadda ya kasance tun yana da shekaru 20.
Yaduwar babban lymphoma B-cell (DLBCL) da sauran ciwon daji na iya zama cikakke a cikin mutanen da suka tsufa.
Hakika, adadin mutanen da suke da shekaru 80 da haihuwa da suka wuce tare da ƙwayar lymphoma mai ƙwayar cuta na B-cell b-cell (B-NHL) ya karu a cikin asibiti. Dokokin jiyya ga DLBCL a cikin ƙananan yara suna da daidaito ko daidaita, a kalla ga halin yanzu. Kokarin kokarin inganta daidaitattun ayyuka tsakanin tasiri da kuma guba sun kasance yanzu ga masu tsufa, ma.
Kadan Mawuyacin
Wata ƙungiyar masana kimiyya da aka sani a duniya na binciken lymphoma - The Groupe d'Etude des Lymphomes de l'Adulte (GELA) - yayi nazarin wannan tambaya a cikin mutanen da ke da shekaru DLBCL 80 zuwa 95. Sunyi bincike ne akan tasiri da aminci na rage kashi na CHOP (doxorubicin, cyclophosphamide, vincristine, da prednisone) chemotherapy tare da wani tsari na al'ada na rituximab - ma'anar kwayoyin halitta guda daya da CD20 '-' a cikin marasa lafiya da DLBCL.
Ya zuwa yanzu, bayan shekaru biyu, sakamakon yana ƙarfafawa, kuma yana nuna muhimmancin masu haƙuri a cikin wannan rukuni. A lokacin da aka yi amfani da tsarin ƙwayar cutar chemotherapy, ko R- "miniCHOP," inganci ya bayyana ya zama daidai a tsawon shekaru 2 zuwa daidaitattun tsari, amma tare da rageccen lokaci na hawan ƙwaƙwalwar cutar shan magani.
Gwaje-gwaje na gaba suna nazarin tambaya game da ko sababbin magungunan bincike na rigakafi da kuma magance hanyoyin kwantar da hankali na iya haɗuwa don rage yawan guba yayin maganin ciwon daji a cikin marasa lafiya.
Sources
Peyrade F, Jardin F, Thieblemont C, et al. Group d'Etude des Lymphomes de l'Adulte (GELA) masu bincike. Aiki na immunochemotherapy (R-miniCHOP) wanda aka samu a cikin tsofaffi marasa lafiya fiye da shekaru 80 tare da babban lymphoma mai ƙwayar jikin B-cell: wani gwaji, guda-ƙarfe, lokaci 2 gwaji. Lancet Oncol . 2011; 12 (5): 460-8.
Iioka F, Izumi K, Kamoda Y, et al. Sakamakon masu tsofaffin marasa lafiya da m B-cell wadanda ba Hodgkin lymphoma bi da tare da rage-kashi chemotherapy. Int J Jarin Gida. 2015 Oktoba 13. [Epub gaba na buga]
Medicine-Based Medicine. https://www.sciencebasedmedicine.org/chemotherapy-doesnt-work-not-so-fast-a-lesson-from-history/. Samun shiga Janairu 2016.
Binciken Tarihin Magunguna. Farkon Mai Ruwa. Samun shiga Janairu 2016.